Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Neuropharmacology. 2019 Jan 8;148:178–188. doi: 10.1016/j.neuropharm.2019.01.003

Figure 4. SK609-induced attentional improvement is blocked by D2/D3R or alpha-1 adrenergic receptor antagonists.

Figure 4.

Rats were treated with SK709 (4mg/kg), raclopride (0.05mg/kg), MPH (2mg/kg), prazosin (0.25mg/kg) or a combination of SK609 with raclopride or prazosin or MPH with raclopride or prazosin and their effects on sustained attention performance was evaluated as difference VI measurements (see methods for details). (A) One-way repeated measures ANOVA indicated a significant of drug (F(4,24)=3.891, p=0.014 corrected for non-homogeneity of variance using Huyn-Feldt correction). Wilcoxon signed rank post hoc tests across select comparisons indicated that the effects of D2/D3 antagonist raclopride significantly differed from SK609 on Difference VI (p = 0.018) and that raclopride pretreatment significantly blocked the effects of SK609 on Difference VI (p = 0.043). No significant differences were observed when comparing the effects of raclopride vs raclopride pretreatment with SK609 (p = 0.735), raclopride vs methylphenidate (p = 0.128), methylphenidate vs raclopride pretreatment with methylphenidate (p = 0.128), or raclopride vs raclopride pretreatment with methylphenidate (p = 0.237). (B) One-way repeated measures ANOVA indicated a significant of drug (F(4,24)=5.312, p=0.048 corrected for non-homogeneity of variance using Huyn-Feldt correction). Wilcoxon signed rank post-hoc tests across select comparisons indicated that the effects of alpha 1 antagonist prazosin significantly differed from SK609 (p = 0.018) and methylphenidate (p = 0.028) on Difference VI and that prazosin pretreatment significantly blocked the effects of SK609 (p = 0.028). No significant differences were observed when comparing the effects of prazosin vs prazosin pretreatment with SK609 (p = 0.108), methylphenidate vs prazosin pretreatment with methylphenidate (p = 0.206), or prazosin vs prazosin pretreatment with methylphenidate (p = 0.063). Data represent mean ± s.e.m: *p<0.05.